In Silico Evaluation of (3R,4R)-Piperidine-Pyrrolopyrimidine Derivatives as Potential Anticancer Agents Targeting Topoisomerase I/II, Bcl-2, and HDAC2
DOI:
https://doi.org/10.32628/IJSRSET2512407Keywords:
Piperidine, Pyrrolopyrimidine, Molecular Docking, MM-GBSA, QSAR, ADMET, Topoisomerase, HDAC2, Bcl-2, In Silico ScreeningAbstract
The development of novel anticancer therapeutics is a critical and ongoing challenge in medicinal chemistry. Heterocyclic scaffolds such as pyrrolo[2,3-d]pyrimidines and piperidine-based structures have demonstrated remarkable activity across various biological targets, particularly in oncology. This study investigates a series of (3R,4R)-piperidine-pyrrolopyrimidine derivatives through comprehensive in silico methodologies. Targeting Topoisomerase I, Topoisomerase II, Bcl-2, and HDAC2—key proteins in cancer progression and survival—we employed molecular docking, MM-GBSA binding free energy calculations, and quantitative structure–activity relationship (QSAR) modeling. The pharmacokinetic and toxicological properties were predicted using SwissADME, pkCSM, and ProTox-II platforms. Results revealed favorable binding affinities, stable molecular interactions, and acceptable drug-like behavior. The findings support the potential of these compounds as lead candidates for future anticancer development.
📊 Article Downloads
References
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. DOI: https://doi.org/10.3322/caac.21492
Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol. 2005;205(2):275–292. DOI: https://doi.org/10.1002/path.1706
Leoni LM, Bailey B, Reifert J, et al. A pyrrolo[2,3-d]pyrimidine class of antitumor agents. Cancer Res. 2003;63(15):4918–4926.
Denny WA. Piperidine derivatives as anticancer agents. Curr Med Chem. 2004;11(24):3219–3246.
Hartmann RW, Muegge I. Scaffold-based drug design. Nat Rev Drug Discov. 2005;4(4):295–308.
Pommier Y. DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. Chem Rev. 2009;109(7):2894–2902. DOI: https://doi.org/10.1021/cr900097c
Cory S, Adams JM. The Bcl-2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002;2(9):647–656. DOI: https://doi.org/10.1038/nrc883
Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007;26(37):5541–5552. DOI: https://doi.org/10.1038/sj.onc.1210620
Thomas M, Ramakrishnan V, Densmore CL, et al. In silico drug design approaches targeting cancer-related proteins. Curr Pharm Des. 2016;22(5):661–674.
Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455–461. DOI: https://doi.org/10.1002/jcc.21334
Genheden S, Ryde U. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opin Drug Discov. 2015;10(5):449–461. DOI: https://doi.org/10.1517/17460441.2015.1032936
Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7:42717. DOI: https://doi.org/10.1038/srep42717
Pires DE, Blundell TL, Ascher DB. pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J Med Chem. 2015;58(9):4066–4072. DOI: https://doi.org/10.1021/acs.jmedchem.5b00104
Downloads
Published
Issue
Section
License
Copyright (c) 2025 International Journal of Scientific Research in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution 4.0 International License.
